Renal Denervation Market valued at $140 Million in 2022, is projected to witness a CAGR of 40%

BRUSSELS - Sept. 26, 2022 - PRLog -- Approximately 12-15% of the population treated for high blood pressure suffers from resistant hypertension. Renal denervation is a minimally invasive procedure for the treatment of resistant hypertension. As the geriatric population is increasing, the number of people suffering from hypertension and the resistant hypertension is also growing which fueling the growth of the RDN market.

The Global Renal Denervation (RDN) Market is estimated at $140 Million (2022) growing at a CAGR of 40%. The market growth is driven by the growing geriatric population, the increasing prevalence of hypertension, and venture capital funding. The U.S. market is likely to offer high growth opportunities over the next 3-5 years.

Rising Prevalence of Hypertension is driving the Growth of the Renal Denervation Market
According to WHO, as of now more than one billion individuals worldwide suffer from hypertension which is expected to grow to 1.6 billion by 2025. WHO assessed that less than one in five people have their hypertension under control, either due to non-adherence or resistance to medication. This is leading to an increasing prevalence of hypertension/resistant hypertension, thus driving the growth of the renal denervation market.

Explore Premium Report on Global Renal Denervation (RDN) Market @ https://meditechinsights.com/global-renal-denervation-market/

Absence of long-term clinical data and risks associated with RDN procedures fuels the Renal Denervation Market Growth

Though Renal Denervation is perceived as a potential treatment for resistant hypertension, it is a generally new methodology and less data is available on its long-term effects. Due to the limited clinical evidence, the RDN products are available only for investigational purpose in some of the major markets.

For instance,

• The use of Medtronic's Symplicity Spyral RDN System in the U.S., Japan and Canada is limited to investigational purpose. In addition, there are several risks associated with this procedure which limits its applications. Bradycardia occurs in some patients during the procedure.

The RF ablation may cause changes to the wall of the arteries, which can sometimes lead to renal artery stenosis. The imaging used throughout the procedure also has a number of risks. Other difficulties include tearing in the renal arteries and pseudoaneurysm (a bruise caused by a leaking hole in an artery).

Competitive Landscape Analysis of Renal Denervation (RDN) Market
Some topmost industry players operating in the global renal denervation market are Medtronic, Boston Scientific Corporation, St. Jude Medical (Abbott), ReCor Medical (Otsuka), and Terumo Corporation, among others.